乌司他丁联合CRRT用于感染性休克患者的疗效观察  

The efficacy of continuous renal replacement therapy and Ulinastatin in septic shock therpy

作　　者：周东民[1] 安山[1] 黄静[1] 冯艳平[1] 

机构地区：[1]河南省肿瘤医院ICU,450008

出　　处：《中国实用医药》2010年第22期5-6,共2页China Practical Medicine

摘　　要：目的观察乌司他丁联合连续性肾替代治疗(CRRT)应用于感染性休克的临床效果。方法 32例感染性休克患者,常规实施集束化治疗基础上,乌司他丁联合CRRT应用为治疗组(18例),单纯CRRT组为对照组(14例)。比较两组入住ICU天数及临床病死率差异;动态观察两组患者治疗前后血乳酸、C-反应蛋白、IL-1及IL-6的变化,并比较差异。结果治疗组和对照组的入住ICU天数(12.5±6.2dvs14.1±5.7d)及临床病死率(38.9%vs42.9%)均无显著性差异(P>0.05);两组治疗后血乳酸、C-反应蛋白、IL-1及IL-6的水平较治疗前下降明显(P<0.05);治疗组第4、7天血乳酸、C-反应蛋白、IL-1及IL-6水平较对照组下降明显(P<0.05)。结论乌司他丁联合CRRT应用于感染性休克疗效确切,抗炎效果好。Objective To evaluate the effects of Ulinastatin and CRRT in septic shock. Methods Thirty-two patients in septic shock by treatment of Sepsis Bundle were randomly divided into two groups：treatment group ：Ulinastatin and CRRT （ 18 patients） and control group：CRRT only （ 14 patients）. We compared the length of ICU stay and mortality and observed the change of blood lactate and c-reactive protein and IL-1 and IL-6. Results There was no difference in the length of ICU （ 12. 5 ± 6. 2 vs 14. 1 ± 5. 5,P 0. 05） and mortality（ 38. 9% vs 42. 9% ,P 0. 05）. The concentration of blood lactate and c-reactive protein and IL-1 and IL-6 were reduced after treatment in both groups （ P 0. 05） ,especially at 4 and 7 days in treatment group（ P 0. 05）. Conclusion The anti-inflammatory of Ulinastatin and CRRT is better in septic shock.

关 键 词：乌司他丁 连续性肾替代治疗 感染性休克 

分 类 号：R631.4[医药卫生—外科学]